Patents Assigned to Gilead Sciencs, Inc.
  • HIV vaccines and methods of making and using
    Patent number: 11795210
    Abstract: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: October 24, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Xinan Liu, Azure T. Makadzange, Stephen R. Martin, Hesham Shehata, Evguenia Svarovskaia
  • Therapeutic compounds for HIV virus infection
    Patent number: 11787825
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: October 17, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, William J. Watkins
  • 2?-substituted carba-nucleoside analogs for antiviral treatment
    Patent number: 11787832
    Abstract: Provided are compounds of Formula I, as well as pharmaceutical compositions containing compounds of Formula I and methods for treating Orthomyxoviridae virus infections by administering these compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: October 17, 2023
    Assignee: Gilead Sciences, Inc.
    Inventor: Michael O'Neil Hanrahan Clarke
  • Compounds and methods for treatment of viral infections
    Patent number: 11780844
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: October 10, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L. Mackman, Dustin S. Siegel, Xianhuang Zeng
  • Phospholipid compounds and uses thereof
    Patent number: 11773122
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: October 3, 2023
    Assignee: Gilead Sciences. Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Devan Naduthambi, Thomas P. Stratton, Peiyuan Wang
  • Processes and intermediates for preparing MCL1 inhibitors
    Patent number: 11760736
    Abstract: The present disclosure provides methods for preparing MCL1 inhibitors or a salt thereof and related key intermediates.
    Type: Grant
    Filed: March 22, 2022
    Date of Patent: September 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Katrien Brak, Kae M. Bullock, Greg Cizio, Kathy Dao, Darryl D. Dixon, Joshua R. Dunetz, Luke D. Humphreys, Valerie Huynh, Michael A. Ischay, Trevor C. Johnson, Jeffrey E. Merit, Christopher S. Regens, Eric A. Standley, Dietrich P. Steinhuebel, Justin Y. Su, Tao Wu, Marshall D. Young
  • Methods and intermediates for preparing therapeutic compounds
    Patent number: 11760746
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I. or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: September 19, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Sachin Dhar, Alex Goldberg, Lars V. Heumann, Zilin Huang, Vinh Xuan Ngo, Trevor James Rainey, Dietrich P. Steinhuebel, Xianghong Wang, Scott Alan Wolckenhauer
  • Therapeutic compounds
    Patent number: 11753399
    Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: September 12, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas Brizgys, Eda Canales, Chienhung Chou, Michael Graupe, Jiayao Li, Roland D. Saito, Scott D. Schroeder, Winston C. Tse, Qiaoyin Wu, Jennifer R. Zhang
  • Therapeutic compositions for treatment of human immunodeficiency virus
    Patent number: 11744802
    Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: September 5, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
  • Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
    Patent number: 11738013
    Abstract: Provided are methods for treating hepatitis B virus infections by administering a NS5A inhibitor, NS5B inhibitor, a NS3 inhibitor, or combinations thereof.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Anuj Gaggar, G. Mani Subramanian
  • Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
    Patent number: 11739101
    Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteosome pathway, and method for treating diseases modulated by HPK1.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: August 29, 2023
    Assignees: Nurix Therapeutics, Inc., Gilead Sciences, Inc.
    Inventors: Hunter P. Shunatona, Galen Paul Shearn-Nance, Scott A. Mitchell, John Buell
  • FXR (NR1H4) modulating compounds
    Patent number: 11739065
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: August 29, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • HBV vaccines and methods treating HBV
    Patent number: 11730808
    Abstract: Provided are HBV immunogenic polypeptides, polynucleotides encoding such polypeptides, vectors expressing such immunogenic polypeptides for use in eliciting an immune response against HBV; pharmaceutical and immunogenic compositions and kits comprising such polypeptides, polynucleotides or vectors, and methods of use in treating and/or preventing HBV.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: August 22, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott J. Balsitis, Sarah M. Ahmadi-Erber, Timo Schippers, Sarah Schmidt
  • Prodrugs of 4?-C-substituted-2-halo-2?- deoxyadenosine nucleosides and methods of making and using the same
    Patent number: 11718637
    Abstract: The present disclosure provides prodrugs of 4?-C-substituted-2-halo-2?-deoxyadenoside nucleosides, and compositions, methods, and kits thereof. Such compounds can be useful for treating viral infections including, but not limited to, human immunodeficiency virus.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: August 8, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Richard L. Mackman, Devan Naduthambi, Neil H. Squires
  • IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF
    Publication number: 20230242508
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: August 3, 2023
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
  • Combination formulation of two antiviral compounds
    Patent number: 11707479
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: July 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • GLP-1R modulating compounds
    Patent number: 11702404
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
    Patent number: 11701372
    Abstract: The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott Ellis, Davin S. Rautiola, Dustin S. Siegel, Maria M. Toteva, Adelle A. Vandersteen
  • Thiadiazole IRAK4 inhibitors
    Patent number: 11702414
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • LPA receptor antagonists and uses thereof
    Patent number: 11702407
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 13, 2021
    Date of Patent: July 18, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska